Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer [5]

Annals of Oncology

Volumn 18, Issue 12, 2007, Pages 2045-2046

  Muñoz, Alberto ^a   Carrera, S ^a   Ferreiro, J ^a   de Lobera, A Ruiz ^a   Mane J M ^a   Lopez Vivanco G ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; HFE PROTEIN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CARDIOTOXICITY; CASE REPORT; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FAMILY HISTORY; FEMALE; GENE OVEREXPRESSION; HETEROZYGOSITY; HUMAN; LETTER; LIVER FUNCTION TEST; LIVER TOXICITY; LOADING DRUG DOSE; LYMPHADENECTOMY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; POINT MUTATION; PRIORITY JOURNAL; RETREATMENT; SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; MEMBRANE PROTEINS; POINT MUTATION; RECEPTOR, ERBB-2;

EID: 37349005967     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm515     Document Type: Letter

References (6)

1. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
2. Mackey JR, KB, Clemens M et al. Trastuzumab prolongs progression free survival in hormone-dependent and HER2+ metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl 1): S3a.
3. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
5. Vogel G, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
6. Cobleigh MA, Vogel C, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.